Cargando…

A Case of Sarcoidosis Associated With Anti–Tumor Necrosis Factor Treatment

Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involves the lungs but can affect many organs or tissues in the body, such as the lymphatic system, skin, eyes, and liver. Typical histopathological lesions are noncaseating granulomas in the affected organ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baha, Ayse, Hanazay, Cigdem, Kokturk, Nurdan, Turktas, Haluk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586909/ https://www.ncbi.nlm.nih.gov/pubmed/26425632 http://dx.doi.org/10.1177/2324709615571366

Ejemplares similares

Diagnostic Yield of Transbronchial Biopsy in Comparison to High Resolution Computerized Tomography in Sarcoidosis Cases
por: Akten, H Serpil, et al.
Publicado: (2018)

Tracheal adenoid cystic carcinoma masquerading asthma: A case report
por: Kokturk, Nurdan, et al.
Publicado: (2004)

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
por: Callejas-Rubio, José Luis, et al.
Publicado: (2008)

The relationship between erythema nodosum and prognosis in systemic sarcoidosis: a retrospective cohort study()
por: Afacan Yıldırım, Elif, et al.
Publicado: (2022)

No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis
por: Banse, Christopher, et al.
Publicado: (2013)

Anti‐tumour necrosis factor‐α‐induced lupus in a patient receiving infliximab for sarcoidosis
por: Stranks, Lachlan, et al.
Publicado: (2022)

A case of leukocytoclastic vasculitis associated with anti-tumor necrosis factor therapy
por: Sikorska, Dorota, et al.
Publicado: (2018)

Simultaneous Improvement of Cutaneous Sarcoidosis and Psoriasis Vulgaris on Administration of a Tumor Necrosis Factor Alpha Inhibitor
por: Kim, Young Shin, et al.
Publicado: (2023)

The effect of fluconazole treatment on tumor necrosis factor-alpha production in murine candidiasis.
por: Kalkanci, Ayse, et al.
Publicado: (2002)

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature
por: Park, Su-Kyung, et al.
Publicado: (2017)

Anti-tumor necrosis factor alpha treatment does not influence serum levels of the markers associated with radiographic progression in ankylosing spondylitis
por: Özdemirel, Ali Erhan, et al.
Publicado: (2023)

Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome
por: Lepzien, Rico, et al.
Publicado: (2021)

Repair of local bone erosions by combined treatment with parathyroid hormone, osteoprotegerin and anti-tumor necrosis factor in tumor necrosis factor-transgenic mice
por: Redlich, K, et al.
Publicado: (2003)

Paradoxical Side Effect Related With Anti-Tumor Necrosis Factor Alpha Treatment
por: Aşkın, Ayhan, et al.
Publicado: (2017)

In vivo Anti‐tumor Efficacy of Polyethylene Glycol‐modified Tumor Necrosis Factor‐α against Tumor Necrosis Factor‐resistant Tumors
por: Tsutsumi, Yasuo, et al.
Publicado: (1996)

Predicting the future of anti-tumor necrosis factor therapy
por: Verweij, Cornelis L
Publicado: (2009)

Golimumab: A Novel Anti-Tumor Necrosis Factor
por: Rossini, Maurizio, et al.
Publicado: (2013)

Do females behave differently in COPD exacerbation?
por: Kilic, Hatice, et al.
Publicado: (2015)

Dysphagia: A Rare Presentation of Sarcoidosis
por: Bani Fawwaz, Baha Aldeen, et al.
Publicado: (2021)

2021 Guideline for the Management of COPD Exacerbations: Emergency Medicine Association of Turkey (EMAT) / Turkish Thoracic Society (TTS) Clinical Practice Guideline Task Force
por: Doğan, Nurettin Özgür, et al.
Publicado: (2021)

Induced myelopathy after long-term anti-tumor necrosis factor alpha treatment
por: Modesto, C, et al.
Publicado: (2011)

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
por: Netz, Uri, et al.
Publicado: (2017)

Alopecia secondary to anti-tumor necrosis factor-alpha therapy()
por: Ribeiro, Lara Beatriz Prata, et al.
Publicado: (2015)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
por: Park, Jihye, et al.
Publicado: (2018)

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
por: Buisson, Anthony, et al.
Publicado: (2022)

Respiratory muscle strength in volleyball players suffered from COVID-19
por: Çelik, Zeliha, et al.
Publicado: (2021)

Sarcoidosis with marked necrosis in enlarged lymph nodes mimics mycobacterial infection: a case report
por: Miyashita, Yosuke, et al.
Publicado: (2021)

The Efficacy of Anti-Tumor Necrosis Factor Therapy in Cryopyrin-Associated Periodic Syndromes: A Report of Two Cases
por: Tahghighi, Fatemeh, et al.
Publicado: (2022)

Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis
por: Rivarola, C, et al.
Publicado: (2008)

Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis
por: Deyab, Gia, et al.
Publicado: (2017)

Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan
por: Hwang, De-Kuang, et al.
Publicado: (2018)

Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review
por: Davignon, Jean-Luc, et al.
Publicado: (2018)

Treatment of Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Disease) With Anti-Tumor Necrosis Factor Alpha
por: Guerin, Clemence, et al.
Publicado: (2021)

Whipple’s disease diagnosed during anti-tumor necrosis factor alpha treatment: two case reports and review of the literature
por: Ramos, Jose M., et al.
Publicado: (2015)

Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
por: Cakir, Ozlem Ozer
Publicado: (2019)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Ju Young, et al.
Publicado: (2021)

Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis
por: Atan, Denize, et al.
Publicado: (2013)

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
por: Winthrop, Kevin L., et al.
Publicado: (2009)

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases
por: Kalden, Joachim R
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_8mqnhmqv6e8o8o7dgu1nkihro7